Evolution of Biologics Screening Technologies
Screening for biologics, in particular antibody drugs, has evolved significantly over the last 20 years. Initially, the screening processes and technologies from many years experience with small molecules were adopted and modified to suit the needs of biologics discovery. Since then, antibody drug d...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2013-05-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | http://www.mdpi.com/1424-8247/6/5/681 |
| id |
doaj-b75c4a053ef64280b9f810e804e7fb65 |
|---|---|
| record_format |
Article |
| spelling |
doaj-b75c4a053ef64280b9f810e804e7fb652020-11-25T03:41:52ZengMDPI AGPharmaceuticals1424-82472013-05-016568168810.3390/ph6050681Evolution of Biologics Screening TechnologiesMatthew J. GardenerPeter CariukTristan J. VaughanScreening for biologics, in particular antibody drugs, has evolved significantly over the last 20 years. Initially, the screening processes and technologies from many years experience with small molecules were adopted and modified to suit the needs of biologics discovery. Since then, antibody drug discovery has matured significantly and is today investing earlier in new technologies that commercial suppliers are now developing specifically to meet the growing needs of large molecule screening. Here, we review the evolution of screening and automation technologies employed in antibody discovery and highlight the benefits that these changes have brought.http://www.mdpi.com/1424-8247/6/5/681high throughput screeningassay technologiestherapeutic antibodies |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Matthew J. Gardener Peter Cariuk Tristan J. Vaughan |
| spellingShingle |
Matthew J. Gardener Peter Cariuk Tristan J. Vaughan Evolution of Biologics Screening Technologies Pharmaceuticals high throughput screening assay technologies therapeutic antibodies |
| author_facet |
Matthew J. Gardener Peter Cariuk Tristan J. Vaughan |
| author_sort |
Matthew J. Gardener |
| title |
Evolution of Biologics Screening Technologies |
| title_short |
Evolution of Biologics Screening Technologies |
| title_full |
Evolution of Biologics Screening Technologies |
| title_fullStr |
Evolution of Biologics Screening Technologies |
| title_full_unstemmed |
Evolution of Biologics Screening Technologies |
| title_sort |
evolution of biologics screening technologies |
| publisher |
MDPI AG |
| series |
Pharmaceuticals |
| issn |
1424-8247 |
| publishDate |
2013-05-01 |
| description |
Screening for biologics, in particular antibody drugs, has evolved significantly over the last 20 years. Initially, the screening processes and technologies from many years experience with small molecules were adopted and modified to suit the needs of biologics discovery. Since then, antibody drug discovery has matured significantly and is today investing earlier in new technologies that commercial suppliers are now developing specifically to meet the growing needs of large molecule screening. Here, we review the evolution of screening and automation technologies employed in antibody discovery and highlight the benefits that these changes have brought. |
| topic |
high throughput screening assay technologies therapeutic antibodies |
| url |
http://www.mdpi.com/1424-8247/6/5/681 |
| work_keys_str_mv |
AT matthewjgardener evolutionofbiologicsscreeningtechnologies AT petercariuk evolutionofbiologicsscreeningtechnologies AT tristanjvaughan evolutionofbiologicsscreeningtechnologies |
| _version_ |
1724527789006127104 |